Cite
HARVARD Citation
Mateos, M. et al. (2016). Elotuzumab in combination with thalidomide and low‐dose dexamethasone: a phase 2 single‐arm safety study in patients with relapsed/refractory multiple myeloma. British journal of haematology. pp. 448-456. [Online].